Author： Stamford Jon Willocks Peggy
Publisher： Future Medicine
ISSN： 1758-2024
Source： Neurodegenerative Disease Management, Vol.3, Iss.5, 2013-10, pp. : 393-395
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content
GDNF treatment in Parkinson’s disease: time for controlled clinical trials?
Brain, Vol. 125, Iss. 10, 2002-10 ,pp. :
Access to resources
Recommend
Latrepirdine for Alzheimer’s disease: trials and tribulations
By Sabbagh Marwan N Berk Camryn
Future Neurology, Vol. 5, Iss. 5, 2010-09 ,pp. :
Clinical heterogeneity in newly diagnosed Parkinson’s disease
By Post B. Speelman J. Haan R.
Journal of Neurology, Vol. 255, Iss. 5, 2008-05 ,pp. :
Parkinson’s disease: clinical manifestations and treatment
International Review of Psychiatry, Vol. 12, Iss. 4, 2000-11 ,pp. :